[Expression of SOX10 and GATA3 in breast cancer and their significance].

Objective: To investigate the expression characteristics of SOX10 and GATA3 in breast cancer and the value of their combination. Methods: A total of 360 breast cancer specimens with SOX10 immunohistochemical staining were collected from the Department of Pathology in Shenzhen People's Hospital from 2018 to 2021, including 268 cases with simultaneous SOX10 and GATA3 staining. The expression of SOX10 and GATA3 in primary and metastatic breast cancer was detected, and the correlations between SOX10 and GATA3 and the molecular types and clinicopathological features of breast cancer were compared, and the distribution differences among each group were statistically analyzed. Results: The overall expression of SOX10 and GATA3 in breast cancer were 25.8%(93/360) and 81.7%(219/268), and that in triple negative breast cancer (TNBC) were 83.3%(80/96) and 42.7%(32/75), respectively. SOX10 was strongly associated with TNBC (P<0.001), whereas GATA3 was highly expressed in luminal A, luminal B and HER2 over expression breast cancers (P<0.001). The expression of SOX10 and GATA3 was negatively correlated in TNBC, and the combined expression rates of SOX10 and GATA3 in breast cancer and TNBC could reach 97.8% (262/268) and 94.7%(71/75), respectively. In addition, the expression of SOX10 was closely correlated with high histological grade, high Ki-67 proliferation index and lymph node metastasis, and negatively correlated with AR. The expression of GATA3 was correlated with low histological grade and lymph node metastasis, and positively correlated with AR, and the difference was statistically significant. Conclusions: SOX10 is a sensitive marker of TNBC, while GATA3 is highly expressed in non-triple negative breast cancer. The two complementary, combined application of SOX10-GATA3 can improve the detection rate of breast cancer, especially TNBC. SOX10 is associated with malignant characteristics of the tumor, suggesting that SOX10 can be used as a prognostic marker and potential therapeutic target for breast cancer.目的： 探讨SOX10和GATA3在乳腺癌中的表达特点及其联合应用的价值。 方法： 收集深圳市人民医院病理科2018—2021年行SOX10免疫组织化学染色的乳腺癌标本360例，其中同时行SOX10和GATA3染色的乳腺癌标本268例，分析SOX10和GATA3在原发性及转移性乳腺癌中的表达，并比较二者与乳腺癌分子分型、临床病理特征之间的相关性，统计其在各分组间的分布差异。 结果： SOX10和GATA3在乳腺癌中的总表达率分别为25.8%（93/360）、81.7%（219/268），在三阴型乳腺癌（triple negative breast cancer，TNBC）中的总表达率分别为83.3%（80/96）、42.7%（32/75）。SOX10在TNBC中高表达（P<0.001），而GATA3在luminal A型、luminal B型及HER2过表达型中高表达（P<0.001）。在TNBC中SOX10与GATA3的表达呈负相关，二者联合应用在乳腺癌及TNBC中的表达率可分别高达97.8%（262/268）、94.7%（71/75）。此外，SOX10的表达与高组织学分级、高Ki-67阳性指数及淋巴结转移密切相关，与雄激素受体（AR）呈负相关，GATA3的表达与低组织学分级及淋巴结转移密切相关，与AR呈正相关，差异有统计学意义。 结论： SOX10是TNBC的灵敏标志物，而GATA3在非三阴型乳腺癌中高表达，二者互补，联合应用SOX10及GATA3可提高乳腺癌尤其是TNBC的检出率。此外，SOX10与肿瘤恶性特征相关，提示SOX10可作为乳腺癌预后评估及潜在治疗靶点。.